Morgan Stanley Reaffirms “Overweight” Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)
Morgan Stanley reiterated their overweight rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report released on Friday,Benzinga reports. Morgan Stanley currently has a $72.00 price target on the stock. RYTM has been the subject of a number of other reports. The Goldman Sachs Group raised their price objective on shares […]
Morgan Stanley reiterated their overweight rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report released on Friday,Benzinga reports. Morgan Stanley currently has a $72.00 price target on the stock. RYTM has been the subject of a number of other reports. The Goldman Sachs Group raised their price objective on shares […]
